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Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) is a debilitating disorder 
linked to diverse intracellular infections as well as physiological stress. Cytotoxic lym-
phocytes combat intracellular infections. Their function is attenuated by stress. Despite 
numerous studies, the role of cytotoxic lymphocytes in ME/CFS remains unclear. 
Prompted by advances in the understanding of defects in lymphocyte cytotoxicity, 
the discovery of adaptive natural killer (NK) cell subsets associated with certain viral 
infections, and compelling links between stress, adrenaline, and cytotoxic lymphocyte 
function, we reassessed the role of cytotoxic lymphocytes in ME/CFS. Forty-eight 
patients from two independent cohorts fulfilling the Canada 2003 criteria for ME/CFS 
were evaluated with respect to cytotoxic lymphocyte phenotype and function. Results 
were compared to values from matched healthy controls. Reproducible differences 
between patients and controls were not found in cytotoxic lymphocyte numbers, cyto-
toxic granule content, activation status, exocytotic capacity, target cell killing, or cytokine 
production. One patient expressed low levels of perforin, explained by homozygosity 
for the PRF1 p.A91V variant. However, overall, this variant was present in a heterozy-
gous state at the expected population frequency among ME/CFS patients. No single 
patient displayed any pathological patterns of cellular responses. Increased expansions 
of adaptive NK  cells or deviant cytotoxic lymphocyte adrenaline-mediated inhibition 
were not observed. In addition, supervised dimensionality reduction analyses of the full, 
multidimensional datasets did not reveal any reproducible patient/control discriminators. 
In summary, employing sensitive assays and analyses for quantification of cytotoxic 
lymphocyte differentiation and function, cytotoxicity lymphocyte aberrances were not 
found among ME/CFS patients. These assessments of cytotoxic lymphocytes therefore 
do not provide useful biomarkers for the diagnosis of ME/CFS.
Keywords: chronic fatigue syndrome, myalgic encephalomyelitis, natural killer cells, cytotoxic T cells, lymphocyte 
cytotoxicity, adaptive natural killer cells
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inTrODUcTiOn
Myalgic encephalomyelitis or chronic fatigue syndrome (ME/
CFS) is a heterogeneous disorder of unknown etiology. Different 
sets of criteria have been applied to diagnose the disorder (1–4). 
In the most recent update of the clinical consensus criteria, ME/
CFS is characterized by flares of pronounced physical and/or 
cognitive fatigability and exacerbation of flu-like symptoms in 
response to exertion, which is combined with different neuro-
logical, immunological, and gastrointestinal symptoms that often 
fluctuate in severity (4). These debilitating symptoms reduce the 
patient’s ability to perform daily activities with at least 50% from 
premorbid level over an extended period of time, typically at least 
6 months (4).
Several epidemics of debilitating, long-lasting fatigue have 
been reported, occasionally associated with specific infections 
(5–7). Population-based investigations in the United Kingdom 
have estimated a stable yearly incidence of ME/CFS to 0.015% 
of the population, with a prevalence of approximately 0.1% (8). 
High antibody titers to the herpes viruses such as cytomegalovirus 
(CMV) and Epstein–Barr virus (EBV) in a group of patients with 
a chronic mononucleosis-like phenotype provided initial links 
between infection and ME/CFS (9). Infections by other intracel-
lular pathogens have also been proposed to trigger the disorder 
(10). A prospective study of patients initially presenting with 
acute infection with EBV or two other intracellular pathogens at 
primary health-care centers found that, 6 months postinfection, 
11% of the patients fulfilled ME/CFS criteria, regardless of infec-
tious agent (11). In that study, the risk for development of ME/CFS 
specifically correlated to the severity of the acute illness. Together, 
these observations suggest that impaired immunity to intracel-
lular pathogens may be associated with ME/CFS susceptibility.
Generally referred to as cytotoxic lymphocytes, cytotoxic 
T lymphocytes (CTL) and natural killer (NK) cells use comple-
mentary strategies to protect the host from intracellular patho-
gens. They use somatically recombined or germ line-encoded 
receptors, respectively, for identification of infected cells, but share 
a molecular machinery for target cell killing. In an examination 
of 41 ME/CFS patients, Caligiuri et al. reported a decreased fre-
quency of peripheral blood CD3−CD57+ lymphocytes, primarily 
representing NK cells, whereas frequencies of CD3+CD57+ cells, 
representing CTL, were unperturbed (12). Moreover, 73% of the 
patients displayed low target cell killing, as measured by lysis of 
K562 target cells (12). A number of studies have subsequently 
reported differences in the number, frequency, and function 
of peripheral blood NK  cells from ME/CFS patients (13–15). 
However, other studies, including one study of 31 healthy or 
ME/CFS discordant monozygotic twin pairs, have not found 
such impairments (16–18). Thus, no consensus has been reached 
regarding a link between impaired lymphocyte cytotoxicity and 
ME/CFS. Moreover, possible mechanisms remain unclear.
Underscoring a pivotal role of cytotoxic lymphocytes in 
immunity and control of inflammation, genetic mutations 
impairing lymphocyte cytotoxicity are associated with severe dis-
eases (19, 20). Whereas autosomal recessive nonsense mutations 
cause early-onset, life-threatening hyperinflammatory disorders, 
milder missense mutations are associated with a range of diseases 
encompassing hematologic malignancies, systemic autoimmun-
ity, or severe neurological manifestations (19). Assessment of 
cellular function and protein levels, rather than DNA sequencing, 
offers a more integrated diagnostic approach to finding impair-
ments in cytotoxic lymphocyte function. Sequencing may fail to 
identify mutations in non-coding, regulatory elements of genes 
(21). Technological advances have yielded diagnostic assays with 
high sensitivity and specificity for defects in lymphocyte cytotox-
icity (22, 23). These assays are better suited than previous assays 
to identify patients with partial, primary defects in lymphocyte 
cytotoxicity, which hypothetically may be linked to ME/CFS 
development.
Besides primary defects in lymphocyte cytotoxicity, environ-
mental factors may also influence cytotoxic lymphocyte function. 
Studies have recently uncovered that NK  cells with unique, 
epigenetic adaptive features emerge in a subgroup of individuals 
upon infection with CMV (24, 25), which 60–70% of the popula-
tion is infected by. Adaptive NK cells can persist independently 
of canonical NK  cells and display reduced immunoregulatory 
capacity, thus being devoted to combating infection (26, 27). 
Coinfection with EBV potentiates the effect of CMV on cytotoxic 
lymphocyte differentiation (28). Large expansions of adaptive, 
non-immunoregulatory NK  cells could thereby provide a link 
between certain herpes virus infections, excessive inflammation, 
and development of ME/CFS. Acute stress, another environmental 
factor, functionally inhibits cytotoxic lymphocytes in general and 
NK cells in particular. This process is a catecholamine-dependent 
effect mediated through the β2-adrenergic receptor (29–31). In 
addition to viral infections, acute physical and/or psychological 
stress can promote ME/CFS flares (4). An altered response to 
acute stress, potentially driven by aberrant β2-adrenergic recep-
tors signaling could thus also lead to excessive inflammation and 
thence predispose to ME/CFS.
With this background, extensive analyses of peripheral blood 
cytotoxic lymphocyte phenotype and function in ME/CFS 
patients as compared to matched controls from two independent 
centers were performed, aiming to elucidate whether aberrances 
in lymphocyte cytotoxicity may be associated with ME/CFS.
MaTerials anD MeThODs
Patients and controls
The study was approved by regional Ethical Review Boards in 
Stockholm (EPN Stockholm) and Oslo (REK Sør-Øst C). The 
Swedish patients were recruited at the ME/CFS Rehabilitation 
Unit, Danderyd University Hospital, Stockholm. Controls were 
age and sex matched to the patients for each substudy individually. 
The Norwegian patients were recruited at the CFS/ME Centre, 
Oslo University Hospital, Oslo. Written informed consent was 
obtained from all patients as well as from the healthy controls 
recruited from the Oslo University Hospital Blood Bank. Oral 
informed consent was obtained from healthy controls recruited 
from the Stockholm Blood Bank (for which only sex and age is 
known). All patients fulfilled the Canada criteria for ME/CFS 
(2). Samples from patients were collected at steady state of the 
disorder.
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cells
From the patients in the Stockholm substudy, peripheral 
blood was collected in heparin tubes and processed within 
8 h of venipuncture. Whole blood used for TruCount analyses 
was obtained at this step. Peripheral blood mononuclear cells 
(PBMC) were obtained by density gradient centrifugation 
(Lymphoprep, Axis-Shield, Dundee, Scotland), washed twice in 
PBS, and immediately frozen down in fetal bovine serum (FBS) 
supplemented with 10% dimethylsulfoxide (DMSO, Sigma-
Aldrich, St. Louis, MO, USA). For the Stockholm controls, 
blood was collected in the blood bank. During blood harvest, a 
heparinized blood sample was collected and used for TruCount 
analyses. The harvested blood bag was subsequently centrifuged 
in the blood bank, and a primary buffy coat was obtained. This 
buffy coat was subsequently further purified to PBMC by density 
gradient centrifugation, washed twice in PBS, and immediately 
frozen down in FBS supplemented with 10% DMSO. All this was 
done within 10 h of venipuncture.
In the Oslo substudy, peripheral blood from both patients and 
controls was collected in CPT tubes and processed within 2.5 h of 
venipuncture. PBMC were obtained by centrifugation of the CPT 
tubes, and the pellets were immediately frozen down in a freez-
ing medium containing 45% FCS, 45% Roswell Parks Memorial 
Institute (RPMI), and 10% DMSO.
For phenotypic analyses, the cells were gently thawed the day 
of use directly in ice-cold FACS buffer [PBS with 2% FCS and 
2  mM ethylenediaminetetraacetic acid (Sigma-Aldrich)] and 
counted using a Muse counter (Merck Millipore, Billerica, MA, 
USA) and an LSR Fortessa (BD Biosciences, Franklin Lakes, NJ, 
USA) for the Stockholm and Oslo samples, respectively.
For functional analyses, the cells were gently thawed in RPMI 
1640 media, counted using a Muse counter (Merck Millipore) or 
an LSR Fortessa (BD Biosciences), and transferred to complete 
media [RPMI 1640 supplemented with 10% FBS and 1  mM 
l-glutamine (Hyclone, Logan, UT, USA)] at the approximate 
concentration of 3 × 106 cells/ml. In the case of the Oslo T cell 
stimulations, 1  U DNAse-I (recombinant, Roche, Penzberg, 
Germany) was added, to prevent clotting of cells. All cells were 
subsequently rested at 37°C with 5% CO2 in a humified incubator 
until the next day when experiments were conducted.
For evaluation of exocytosis, three cell lines were used. K562 
is an MHC class 1-deficient erythroleukemia cell line highly 
sensitive to NK  cell killing, Raji is an EBV-transformed B-cell 
line that weakly triggers NK  cell cytotoxicity. P815 is a mouse 
mastocytoma cell line expressing Fc receptors and hence can 
be coated with mouse antibodies specific to human antigens to 
induce redirected lysis. All cell lines were kept in complete media 
and were in logarithmic growth phase when used.
general experimental Design
All experiments, except for the TruCount, were conducted in 
one session. As such, the stainings were simultaneously con-
ducted on PBMC thawed from all individuals from one study 
site (Stockholm or Oslo), eliminating inter-experimental vari-
ability. Details regarding specific assay protocols are provided 
in the Section “Supplementary Methods” in Supplementary 
Material.
Flow cytometry
All flow cytometry was performed on 18-color LSR Fortessa instru-
ments (BD Biosciences). Subsequent flow cytometry file analysis 
was performed with FlowJo (version 9.8.1, TreeStar Inc., Ashland, 
OR, USA). For all flow cytometry assays, fluorochrome-conjugated 
antibodies have been used. See Table S1 in Supplementary Material 
for specifications. In addition to the specified antibodies, a fixable 
dead cell marker (Invitrogen) was used in all stainings. See the 
Section “Supplementary Methods” in Supplementary Material for 
staining protocols and gating strategies.
genetic analyses
Genomic DNA was isolated from peripheral blood according to 
standard procedures. For the patient with low perforin expres-
sion, the coding regions of PRF1 (NM_001083116.1, GRCH37) 
were amplified and sequenced on an ABI 3730 Genetic Analyzer 
(Thermo Fisher Scientific, Waltham, MA, USA). SeqScape 
(Version 2.5; Applied Biosystems) was used for analysis.
For genotyping of the PRF1 p.A91V polymorphism (rs35947132), 
a validated TaqMan genotyping assay (c_25600964_20; 
Thermo Fisher Scientific) was used according to the manufacture’s 
instructions. Reactions were performed in duplicates, with posi-
tive (heterozygous and homozygous for the polymorphism) and 
negative controls included in each experiment. End point fluo-
rescence detection was performed post-PCR on a QuantStudio 7 
Flex Real-Time PCR System (Life Technologies, Thermo Fisher 
Scientific). Results were analyzed with the QuantStudio 6 and 7 
Flex Software.
statistical analyses
To decrease α-error rates due to multiple testing, only findings with 
p-values less than 0.01 are reported in the manuscript. Further, only 
values meeting the Holm–Bonferroni (32) correction for multiple 
testing are reported as significant. The Holm–Bonferroni correc-
tion was applied separately to each subfigure. To decrease β-error 
rates, the chosen α-error rate for the Holm–Bonferroni corrected 
p-values was 0.1, as all findings in the Stockholm substudy were 
confirmed in the Oslo substudy, and thus a value with p = 0.1 
in both studies equals 0.1 × 0.1 = 0.01. Specific descriptions on 
statistical procedures, including data preprocessing, principal 
component (PC), and sparse partial least squares discriminant 
analyses, are described in the Section “Supplementary Methods” 
in Supplementary Material.
graphical layouts
Tables have been generated using Excel software (Microsoft, 
version 14.4.9, Redmond, WA, USA). Figures have been gener-
ated using Prism (version 6.0b, GraphPad, La Jolla, CA, USA), R 
[version 3.2 (33)] including package ggplot2 (34) and gplots (35) 
and Illustrator (version 16.0.0, Adobe, San Jose, CA, USA).
resUlTs
Patient and control characteristics
All 48 patients fulfilled Canada 2003 (2) criteria for ME/CFS. The 
clinical characteristics of the groups are summarized in Table 1 and 
Table 1 | Participant characteristics.
sample group number of 
participants
age Females, % Duration >2 years, % infectious trigger, % cytomegalovirus positive  
(n analyzed)
Median range
Stockholm Patient 24 44 34–63 75 100 83 53 (17)
Control 28 44 24–65 71 – – 64 (28)
Oslo Patient 24 30 18–52 79 88 96
Control 24 30 20–46 79 – –
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Table S1 in Supplementary Material. The healthy control and patient 
groups were matched in terms of age and gender. In the Stockholm 
and Oslo patient groups, respectively, 100 and 88% of the patients 
suffered from ME/CFS for more than 2  years. An association 
between infection or vaccination and ME/CFS debut was noted in 
83 and 96% of the cases from Stockholm and Oslo, respectively.
evaluation of Peripheral blood cytotoxic 
lymphocyte numbers and activation 
status
In an effort to acquire possible evidence for primary defects 
in lymphocyte cytotoxicity underlying ME/CFS, we wished to 
evaluate multiple aspects of cytotoxic lymphocyte function. A 
prerequisite for lymphocyte cytotoxicity is normal development 
and survival of cytotoxic lymphocyte subsets. Studies of ME/CFS 
patients have described decreased numbers of certain cytotoxic 
lymphocyte subsets (12, 13). Thus, we examined the numbers of 
four CD8+ T cell and NK cell subsets in the peripheral blood of 
ME/CFS patients. Among CD8+ T cells, CD3+CD4−CD8+CD57− 
cells represent predominately non-cytotoxic subsets, whereas 
CD3+CD4−CD8+CD57+ T cells are bona fide cytotoxic effectors 
(23, 36). Peripheral blood NK cells can be grossly divided into 
CD3−CD56bright immunoregulatory NK  cells and CD3−CD56dim 
NK  cells with a strong cytotoxic capacity. Whole blood from 
patients and controls from Stockholm was collected, stained 
within 6 h of venipuncture, and analyzed by flow cytometry. No 
significant differences between patients and controls were identi-
fied with respect to the absolute numbers of peripheral blood 
CD8+ T cell or NK cell subsets (Figure 1A). Peripheral blood cell 
counts were not assessed in the Oslo substudy.
Previous reports have also described low levels of perforin in 
NK cell subsets (37). Congenital perforin deficiency results in fatal, 
infantile hyperinflammatory disorders (38). Granzyme A and B 
facilitate perforin-dependent cytotoxicity, diffusing into the target 
cell through pores formed by perforin and inducing apoptosis 
through protease activity. Although no patients with GZMA or 
GZMB mutations have so far been identified, Gzma and Gzmb 
double knockout mice develop hyperinflammatory disease upon 
viral infection (38). Expression levels of these cytotoxic granule 
constituents were therefore determined in CD8+ T cell and NK cell 
subsets from ME/CFS patients. PBMC were thawed, surface 
stained with antibodies to lineage markers, fixed, permeabilized, 
and stained intracellularly with antibodies to perforin, granzyme 
A, and granzyme B. Cells were analyzed by flow cytometry. 
Contrasting some previous reports, no systematic differences were 
identified with respect to cellular content of perforin (Figure 1B). 
One patient did, however, express low levels of perforin in CD8+ 
T  cell and NK  cell subsets. In this patient, sequencing revealed 
homozygosity for the PRF1 p.A91V variant. When screening 
through all 24 Norwegian and 17 of the Swedish patient samples for 
which DNA was available, an additional three Swedish patients and 
one Norwegian patient were heterozygous for this PRF1 variant. 
Thus, the carriership of the PRF1 p.A91V variant among the ana-
lyzed patients (minor allele frequency 6/82 alleles, i.e., 7.3%), was 
comparable to that of >30,000 individuals in the European Exome 
Aggregation Consortium (minor allele frequency 4.7%) (39).
No differences were detected in regards to granzyme B expres-
sion among the cytotoxic CD8+ T cell or NK cell subsets from 
the Stockholm or Oslo patient samples (Figure 1B). However, in 
the non-cytotoxic CD8+CD57− T cells, granzyme A levels were 
lower among the ME/CFS patients from Stockholm as compared 
to controls (p = 0.005, not significant after correction for multiple 
testing). There was a similar, insignificant tendency in the Oslo 
sample (p = 0.14) (Figure 1C).
Studies of ME/CFS patients have found increased CD69 expres-
sion on NK cells (40), decreased CD38 (40) or, by comparison to 
MS patients, increased CD38 and HLA-DR expression on CD8+ 
T cells (41), suggesting aberrant activation of cytotoxic lympho-
cytes in ME/CFS patients. Cell proliferation, measured by Ki67, 
has also been reported to be low, albeit selectively in CD4+ T cells 
(40). Thus, we examined expression of activation and proliferation 
markers in the four CD8+ T and NK  cell subsets. PBMC were 
thawed, stained with antibodies to lineage markers as well as CD38, 
CD69, CD279 (PD-1), and HLA-DR, fixed, permeabilized, and 
stained intracellularly with an antibody to Ki67. Cells were ana-
lyzed by flow cytometry. In the patients from Stockholm, HLA-DR 
levels were higher on CD56dim NK cells from the ME/CFS patients 
compared to controls (p =  0.002, significant after correction for 
multiple testing) (Figure 1D). No other differences were noted. In 
the Oslo substudy, the HLA-DR levels on CD56dim NK cells were 
equal between the groups (p = 0.52), and no other differences were 
noted (Figure  1E). In summary, the ME/CFS patients exhibited 
normal numbers of cytotoxic lymphocytes that displayed normal 
cytotoxic protein content overall normal activation status. A 
non-significant trend for decreased granzyme A was noted in non-
cytotoxic CD8+CD57− T cells from ME/CFS patients.
evaluation of Peripheral blood cytotoxic 
lymphocyte Function
Dysfunction in lymphocyte cytotoxicity has been denoted a 
hallmark of ME/CFS (42). Apart from perforin deficiency, 
the majority of the molecularly defined defects in lymphocyte 
cytotoxicity arise from aberrances cytotoxic granule exocytosis 
(19). Parallel valuation of T cell and NK cell responses can increase 
FigUre 1 | Continued
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FigUre 1 | Continued  
Cytotoxic lymphocyte counts, granule content, or activation status do not differ between ME/CFS patients and controls. (a) Absolute count of cytotoxic 
lymphocytes in whole blood from the Stockholm substudy. Whole blood was stained in tubes with predefined numbers of beads, and the bead-cell mix was 
analyzed with flow cytometry. Four CD8+ T cell and natural killer (NK) cell subsets are shown. (b,c) Phenotypic analysis of cytotoxic proteins in cytotoxic 
lymphocytes. Peripheral blood mononuclear cells (PBMC) were thawed, counted, and stained with antibodies to cytotoxic proteins and lineage markers. The level of 
perforin and granzyme A and B protein expression in four CD8+ T cell and NK cell subsets from Stockholm and Oslo is shown. ΔMFI = median fluorescence 
intensity after subtraction of median fluorescence intensity for isotype controls. CD57−CD8+ T cells are shown separately, as the cytotoxic proteins are expressed 
bimodally in these cells. (D,e) Phenotypic analysis of activation and mitosis status in cytotoxic lymphocytes. PBMC were thawed, counted, and stained with 
antibodies to activation and mitosis markers as well as lineage markers. (D) Percentage of four CD8+ T cell and NK cell subsets from the Stockholm substudy that 
are positive for the activation markers CD38, CD69, CD279, and HLA-DR and the mitosis marker Ki67. (e) Percentage of four CD8+ T cell and NK cell subsets from 
the Oslo substudy that are positive for the activation markers CD38, CD69, CD279, and HLA-DR. Gray boxes depict control values, whereas black boxes depict 
patient values. Lines through boxes show the median. Error bars extend to 5th and 95th percentile. Dots show outliers. 24 patients and 28 controls for the 
Stockholm substudy and 24 patients and 24 controls [20 patients and 23 controls for panel (e)] for the Oslo substudy are included in the analyses.
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sensitivity for the identification of primary defects in cytotoxic 
granule exocytosis (23). Furthermore, NK  cells can be activated 
through multiple co-activating receptor combinations (43). Thus, 
potential selective defects in specific receptor signaling pathways 
may only be identified through comprehensive screening of dif-
ferent stimulations. For these reasons, the exocytic capacity of 
specific CD8+ T cell and NK cell subsets from ME/CFS patients 
was investigated following multiple different stimuli. PBMC were 
thawed and rested overnight in complete medium. The cells were 
subsequently stimulated with medium alone, P815 cells, P815 cells 
supplemented with anti-CD3 antibody (clone S4.1), P815 cells 
supplemented with anti-CD16 or with anti-CD226 (DNAM-1) and 
anti-CD244 (2B4) antibodies, K562 cells, Raji cells, Raji cells sup-
plemented with Rituximab (inducing NK cell antibody-dependent 
cellular cytotoxicity). After 4 h, the cells were surface stained with 
antibodies to lineage markers, as well as CD107a, and analyzed 
by flow cytometry. No significant differences were seen between 
the patients and the controls for any of the subsets or stimulations 
(Figure  2A). Moreover, in a follow-up experiment in the Oslo 
substudy with a similar setup, but where only P815, P815 with anti-
CD3 (clone UCHT.1), P815 cells supplemented with anti-CD16 or 
with anti-CD226 (DNAM-1), and anti-CD244 (2B4) antibodies 
were investigated, no differences were observed (Figure  2B). In 
addition, there was no difference in regards to the number of low 
responders between the controls and the patients (Figures 2A,B).
Deficient NK cell-mediated cytotoxicity has previously been 
linked to ME/CFS (12, 44). Although cytotoxic lymphocyte gran-
ule content and exocytic capacity was not impaired in the ME/
CFS patients, we nonetheless examined the ability of NK cells to 
kill target cells using a 51Cr release assay. 51Cr-labeled K562 target 
cells are frequently employed for the diagnostics of patients with 
defective lymphocyte cytotoxicity (45). PBMC from all patients 
and controls in the Stockholm substudy were simultaneously 
thawed, rested overnight in complete medium, and evaluated 
for lysis of 51Cr-labeled K562 cells. Killing by NK cells from ME/
CFS and healthy controls was similar at the examined effector 
to target ratios (Figure  2C). Following this, an analysis of the 
linear regression coefficients for the number of lytic units as a 
function of the NK cell percentage among PBMC was performed 
for each individual, reflecting the per-cell cytotoxic efficiency. 
Comparison between the patient and healthy control group 
revealed no significant difference (Figure 2D). A few outliers with 
a lower cytotoxicity were identified, but these were all among the 
healthy controls (Figures 2C,D). An identical experiment with 
15 and 16 of the Oslo patients and controls, respectively, was also 
performed. Consistent with results from the Stockholm substudy, 
no differences between the groups were seen (Figures  2E,F). 
Thus, neither the release of cytotoxic granules after multiple dif-
ferent stimuli nor cytotoxicity was impaired in ME/CFS patients 
as compared to controls.
evaluation of Peripheral blood cytotoxic 
lymphocyte Pro-inflammatory cytokine 
Production
In addition to killing, target cell-mediated activation of cytotoxic 
lymphocyte induces production of pro-inflammatory cytokines. 
Such cytokines are central to the defense against intracellular 
pathogens. To evaluate cytokine production ability, PBMC from 
the Stockholm substudy were thawed and rested overnight in 
complete medium. The cells were subsequently stimulated with 
medium alone, P815 cells, P815 cells supplemented with anti-
CD3 antibody (clone S4.1), P815 cells supplemented with anti-
CD16 or with anti-CD226 (DNAM-1) and anti-CD244 (2B4) 
antibodies, K562 cells, Raji cells, and Raji cells supplemented 
with Rituximab. After 4  h, the cells were surface stained with 
antibodies to lineage markers, fixed, permeabilized, stained 
intracellularly with antibodies to IFN-γ and TNF, and analyzed 
by flow cytometry. CD56dim NK  cells from ME/CFS patients 
produced more IFN-γ after stimulation with P815 and anti-CD16 
antibody than controls (p = 0.009, not significant after correction 
for multiple testing), and a similar trend was seen for CD56bright 
NK cells (Figure 3A). No clear differences were noted for TNF 
(Figure  3B). A follow-up experiment was performed for the 
Oslo substudy with a similar setup, but where only P815, P815 
with anti-CD3 (clone UCHT.1), and P815 cells supplemented 
with anti-CD16 or with anti-CD226 and anti-CD244 antibodies 
were investigated. Here, no differences between the patients and 
controls were observed (Figures 3C,D). Thus, although a trend 
toward cytokine hyperresponsivity by ME/CFS patients was 
noted in the Stockholm substudy, no such trend was observed in 
the Oslo substudy.
assessment of adaptive nK cell 
Frequencies in Me/cFs Patients
After the investigation of direct aberrances in phenotype and 
function of cytotoxic lymphocytes in ME/CFS, evaluation 
cytotoxic lymphocyte functionality resulting from environ-
mental exposures followed. As a first step, the frequencies of 
adaptive CD56dim NK cell subsets from the Stockholm and Oslo 
FigUre 2 | Assessment of exocytosis as well as K562 killing is not different between ME/CFS patients and controls. (a,b) Analysis of exocytosis. Peripheral blood 
mononuclear cells (PBMC) were thawed, rested overnight, and then stimulated for 4 h with no target, P815 + anti-CD3, K562, Raji, Raji + Rituximab, P815, 
P815 + anti-CD16, P815 + anti-CD244 (2B4) + anti-CD226 (DNAM-1), and subsequently stained with antibodies to CD107a in combination with lineage markers. 
Percentage of four CD8+ T cell and natural killer (NK) cell subsets positive for CD107a in the Stockholm and Oslo substudies, respectively, is shown. Gray boxes 
depict control values, whereas black boxes depict patient values. Lines through boxes show the median. Error bars extend to 5th and 95th percentile. Dots show 
outliers. (c,e) K562 lysis of NK cells from the Stockholm and Oslo substudies. NK cell activity measured with K562 lysis. K562 cells were labeled with 51Cr, and 
subsequently cocultured with PBMC for 4 h at six standardized PBMC concentrations. Subsequently, gamma emissions from the supernatants were registered. 
X-axis shows the NK:target ratio, with the target set to 1. The NK cell values are estimated from average percentage of NK cells in simultaneously performed flow 
cytometric assay. Y-axis shows lytic units, calculated with the formula (100 × (x − min)/(max − min)), where x = average value from duplicates or triplicates 
(Stockholm and Oslo analysis, respectively), min = average value from negative control triplets, max = average value from positive control triplets. Gray dots depict 
control values; black dots depict patient values. (D,F) Regression coefficients for the lytic units as a function of the NK:target ratio calculated for every individual for 
the Stockholm and Oslo analysis, respectively. Gray boxes depict control values, whereas black boxes depict patient values. Lines through boxes show the median. 
Error bars extend to 5th and 95th percentile. Dots show outliers. 24 patients and 28 controls for the Stockholm substudy and 22 patients and 24 controls [15 
patients and 16 controls for panels (e,F)] for the Oslo substudy are included in the analyses.
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FigUre 3 | Pro-inflammatory cytokine production is similar between ME/CFS patients and controls. (a–D) Analysis of cytokine production. Peripheral blood 
mononuclear cells were thawed, rested overnight, and then stimulated for 4 h with no target, P815 + anti-CD3, K562, Raji, Raji + Rituximab, P815, P815 + anti-
CD16, P815 + anti-CD244 + anti-CD226 (DNAM-1), and subsequently stained with antibodies to lineage markers, fixed, permeabilized, and stained intracellularly 
for IFN-γ and TNF. (a) Percentage of four CD8+ T cell and natural killer (NK) cell subsets positive for IFN-γ in the Stockholm substudy. (b) Percentage of four CD8+ 
T cell and NK cell subsets positive for TNF in the Stockholm substudy. (c) Percentage of four CD8+ T cell and NK cell subsets positive for IFN-γ in the Oslo 
substudy. (D) Percentage of four CD8+ T cell and NK cell subsets positive for TNF in the Oslo substudy. Gray boxes depict control values, whereas black boxes 
depict patient values. Lines through boxes show the median. Error bars extend to 5th and 95th percentile. Dots show outliers. 24 patients and 28 controls and 22 
patients and 24 controls for the Stockholm and Oslo substudies, respectively, are included in the analyses.
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substudies were determined, as this cell population displays 
reduced immunoregulatory capacity and is strongly associated 
with CMV infection. PBMC were thawed, surface stained with 
antibodies to lineage markers and NKG2C, fixed, permeabilized, 
and stained intracellularly with antibodies to FcεRγ EAT-2, SYK, 
and PLZF. Increased frequencies of adaptive CD56dim NK  cell 
subsets were not observed in samples from either Stockholm or 
Oslo (Figures  4A–C). To investigate the coexpression patterns 
FigUre 4 | Investigation of expanded adaptive natural killer (NK) cell subsets does not reveal any differences between ME/CFS patients and controls. (a–D) 
Analysis of percentages of adaptive NK cell expansions. Peripheral blood mononuclear cells were thawed and stained with antibodies to lineage markers, NKG2C, 
and a dead cell marker, fixed, permeabilized, and stained intracellularly for FcεRγ, SYK, EAT-2, and PLZF. (a) Gating strategy for one representative donor is shown. 
Histograms depict one donor without and one donor with adaptive NK cell expansions. (b,c) Percentage of CD3−CD56dim NK cells positive for NKG2C, FcεRγ, 
SYK, EAT-2, and PLZF in the Stockholm and Oslo substudies, respectively. Adaptive NK cells express combinations of high NKG2C and low FcεRγ, SYK, EAT-2, 
and PLZF. Gray boxes depict control values, whereas black boxes depict patient values. Lines through boxes show the median. Error bars extend to 5th and 95th 
percentile. Dots show outliers. (D) Pie charts of Boolean analyses of subsets expressing any combination of NKG2C, FcεRγ, SYK, EAT-2, and PLZF. If an arc is 
drawn over a specific pie slice, then the connected marker is present on the pie slice in question. Following this, the majority of cells are positive for FcεRγ, SYK, 
EAT-2, and PLZF, and thus non-adaptive. 24 patients and 28 controls and 24 patients and 24 controls for the Stockholm and Oslo substudies, respectively, are 
included in the analyses.
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FigUre 5 | Adrenaline inhibition is not significantly different between ME/CFS patients and controls. (a,b) Analysis of exocytosis, IFN-γ, and TNF production after 
inhibition with adrenaline in the Stockholm substudy. Peripheral blood mononuclear cells were thawed, rested overnight, preincubated for 30 min without or with 
adrenaline at three concentrations and then stimulated for 4 h with P815 or P815 + anti-CD16, and subsequently stained with antibodies to CD107a in combination 
with lineage markers, fixed, permeabilized, and stained intracellularly for IFN-γ and TNF. (a) Percentage of CD3−CD56bright natural killer (NK) cells positive for CD107a, 
IFN-γ, or TNF. (b) Percentage of CD3−CD56dim NK cells positive for CD107a, IFN-γ, or TNF. 24 patients and 28 controls from the Stockholm substudy are included 
in the analyses.
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of NKG2C, FcεRγ EAT-2, SYK, and PLZF in NK cells, a Boolean 
gating strategy was applied that identified all possible com-
binations of these markers in the Oslo substudy. There was no 
subset with any combination of markers that differed between the 
patient and control groups (Figure 4D). Thus, the hypothesis that 
expansions of epigenetically modified NK cells may play a role in 
ME/CFS is not supported.
adrenergic regulation of Peripheral blood 
cytotoxic lymphocyte Function
Physical and psychological stress can precipitate ME/CFS 
symptoms (2). Cytotoxic lymphocytes function is attenuated by 
adrenaline-mediated stress responses, thus providing a possible 
link between ME/CFS and impairments in cytotoxic lympho-
cytes. To probe for a possible aberrance in the inhibitory capacity 
of adrenaline on cytotoxic lymphocyte function in ME/CFS, an 
experiment in the Stockholm substudy was performed. PBMC 
were thawed, rested overnight in complete medium, and subse-
quently preincubated with 1, 0.1, and 0.01 µM of adrenaline or 
medium alone. Thereafter, P815 cells or P815 cells supplemented 
with anti-CD16 antibody were added to each well. After 4 h, the 
cells were stained with antibodies to lineage markers and CD107a, 
fixed, permeabilized, and stained intracellularly with antibod-
ies to IFN-γ and TNF (Figures 5A,B). The CD56dim cells from 
ME/CFS patients tended to display less inhibition of the IFN-γ  
production at 0.1 and 0.01  µM compared to the controls 
(p = 0.004 and 0.009, respectively, significant after correction 
for multiple comparisons) (Figure 5B). In summary, a slightly 
weaker effect of adrenaline inhibition on cytokine production 
from cytotoxic lymphocytes after receptor stimuli could be 
present.
identification of Patient/control 
Discriminators in the Full, 
Multidimensional Dataset
Individual analyses of cytotoxic lymphocyte phenotypic or func-
tional parameters might not identify patterns of mild deficiencies 
that taken together could have an impact on lymphocyte cyto-
toxicity. Moreover, studies have indicated that subgroups of ME/
CFS patients may exist (46–48). Thus, to identify such potential 
subgroups and patterns of mild deficiencies, supervised and 
unsupervised dimensionality reduction techniques were utilized 
on the full substudy datasets.
To elucidate whether the participant class (being a patient or 
control) was contributing to the overall variance in the dataset, PC 
analyses including all 51 common investigated parameters (Table 2), 
were conducted for all the complete cases from the Stockholm 
and Oslo substudies separately. Briefly, the first PC is defined as 
the vector through a multidimensional data cloud that explains the 
Table 2 | Parameters common to the Stockholm and Oslo substudies used for 
identification of patient/control discriminators.
cD3+cD4−cD8+ cD3−
cD57− cD57+ cD56bright cD56dim
Perforin x x x x
Granzyme A x x x x
Granzyme B x x x x
CD38 x x x x
CD69 x x x x
CD279 x x x x
HLA-DR x x x x
P815+anti-CD3: CD107a x x – –
P815+anti-CD3: IFN-γ x x – –
P815+anti-CD3: TNF x x – –
P815+anti-CD16: CD107a – – x x
P815+anti-CD16: IFN-γ – – x x
P815+anti-CD16: TNF – – x x
P815+anti-CD226+anti-
CD244: CD107a
– – x x
P815+anti-CD226+anti-
CD244: IFN-γ
– – x x
P815+anti-CD226+anti-
CD244: TNF
– – x x
NKG2C – – – x
EAT-2 – – – x
FcεRγ – – – x
SYK – – – x
PLZF – – – x
x Included parameter Parameter contributing to 
Stockholm sPLS-DA vector– Not included parameter
Parameter contributing to  
Oslo sPLS-DA vector
Parameter contributing to  
both sPLS-DA (none)
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separation of the groups in the Oslo substudy, sparse projection to 
latent structures discriminant analyses (sPLS-DA) were performed 
on all 51 common, transformed immunological parameters for 
the Stockholm and the Oslo substudies separately. sPLS-DA 
is a supervised method that identifies the vector(s) through a 
multidimensional data cloud that separates the predefined classes 
at maximum. By using a penalty for low or absent contribution, 
variables that contribute to such a discriminant vector are identi-
fied (49). As the dataset in this case was structured into two classes 
(patient or control), models with one discriminant vector were 
chosen in accordance with previous literature (50). To increase 
the robustness of the analysis, a bootstrapped sPLS-DA algorithm 
was used (51). For the Stockholm and Oslo substudy analysis, 
respectively, 14 and 1 immunological parameters were identified 
that contributed to the discriminant vector (Table 2; Figure 6B). 
Following this, the discriminant vector from Stockholm was 
reconstructed by multiplying the same immunological parameters 
from Oslo, with the Stockholm discriminant vector loadings, 
and vice versa. These “synthetic” discriminant vectors were then 
used for prediction purposes by generating receiver-operating 
characteristic curves (Figure  6C). In this analysis, the optimal 
prediction for the Stockholm substudy based on the result from 
the Oslo sPLS-DA was around 70% in specificity and sensitivity. 
In the opposite analysis, the optimal sensitivity/specificity was 
around 60%. Thus, none of the identified discriminant vectors 
could separate cases from controls in the other substudy.
Possible subgrouping based on clinical parameters was explored. 
Patients included in this study had generally been suffering of ME/
CFS for >2 years, and an infectious trigger was present in a clear 
majority of the cases, preventing subgrouping in these parameters. 
However, 20 clinical assessments of pain, fatigue, muscle pain, etc. 
(listed in Table S1 in Supplementary Material) were available for 
all patients. Hypothetically, identifying clinical parameters that 
correlate to laboratory findings could provide a base for further 
stratification of subgroups. Thus, Pearson product-moment cor-
relations between the 51 cytotoxic lymphocyte parameters shown 
in Table 2, and the 21 clinical assessments were performed for the 
Stockholm and Oslo substudies individually. This generated two 
matrices with 21 × 51 correlation coefficients and two equally sized 
matrices with the correlation p-values. When these 1,071 correla-
tion coefficients and their respective p-values were compared, no 
correlation was less than 0.01 for both substudies (Figure 6D). No 
further subgroup stratification was therefore attempted. In sum-
mary, no patterns of laboratory or clinical findings separated all or 
subgroups of patients from the controls either using unsupervised 
or supervised methods.
DiscUssiOn
Traditionally, primary immunodeficiencies (PIDs) have been 
regarded as severe monogenetic defects with high penetrance, 
resulting in often fatal syndromes in infants. This view is chang-
ing, and PIDs are rather viewed as a spectrum of disorders 
ranging from fatal syndromes in infancy to diseases presenting 
in adulthood, limited to recurrent infections with specific patho-
gens or even including autoimmunity (52). Whereas autosomal 
recessive mutations abrogating cytotoxic function invariably 
most variance. The second PC is then defined as the vector with the 
second most variance, with the constraint that this vector must be 
orthogonal to the first PC. All following PCs relate to the previous 
ones in the same way. In this unsupervised method, the first 14 
PCs were investigated. These explained 81 and 86% of the total 
variance in the Stockholm and Oslo data, respectively (Figure 
S2A and Table S3 in Supplementary Material). In the Stockholm 
analysis, patient/control separation was evident in the fifth PC. This 
PC explained 7% of the Stockholm dataset variance. Thus, it could 
be assumed that participant class explained ≈7% of the variance in 
the Stockholm dataset. No class separation was evident in the Oslo 
PCA. In addition, no clusters of patient subgroups were evident in 
any of the components (Figure 6A; Figure S2B in Supplementary 
Material).
To explore the separation of patients and controls in the 
Stockholm substudy further and to search for any meaningful 
FigUre 6 | Continued  
Multidimensionality approaches do not reveal parameter combinations that 
can separate both Oslo and Stockholm patients from controls. Separate 
analyses for the Stockholm and Oslo substudies are represented in the first 
and second column, respectively. (a) Principal component (PC) analysis. X- 
and Y-axes show the estimated PC1 and PC2, respectively. Black and green 
dots indicate control and ME/CFS individuals, respectively.  
(b) Histograms show the sparse partial least squares discriminant 
components for the separate analyses. Gray and green colors indicate 
controls and ME/CFS patients, respectively. (c) Receiver-operating 
characteristic (ROC) curves are shown. The left ROC curve is based on a 
crossover discriminant component of Stockholm dataset generated by 
multiplying the variable and the loading identified in the Oslo sPLS-DA. The 
right ROC curve is generated in the corresponding way for the Oslo dataset. 
(D) Oslo Pearson product-moment correlation coefficients are plotted as a 
function of Stockholm Pearson product-moment correlation coefficients for 
correlations of clinical vs cytotoxic lymphocyte parameters. Gray dots show 
correlations that are insignificant in both substudies. Red and green dots 
show significant correlations in the Stockholm and Oslo substudies, 
respectively. Yellow dots should show correlations that overlap between the 
analyses (none present). For the Stockholm and Oslo substudies, respectively, 
23 + 28 and 20 + 23 patients + controls are included in the analyses.
FigUre 6 | Continued
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manifestations (19). Heterozygous carriership of such mutations 
increases the risk of malignancy (20). Notably, animal models 
and certain observations in humans implicate intracellular infec-
tions as triggers of diverse clinical manifestations. Prompted by 
an association between intracellular infections and development 
of the ME/CFS as well as several reports of impaired NK  cell 
function in ME/CFS patients, we investigated if ME/CFS might 
represent a relatively mild manifestation of PID caused by 
impaired lymphocyte cytotoxicity. To this end, recently improved, 
sensitive and specific assays that readily identify patients with 
primary defects in lymphocyte cytotoxicity were used (23, 53). 
Our analyses did not uncover any systematic evidence for defects 
in lymphocyte cytotoxicity, in individual patients or the patient 
groups as a whole. One individual was homozygous, and four 
were heterozygous for the PRF1 p.A91V variant, associated 
with impaired lymphocyte cytotoxicity and an increased risk of 
certain malignancies (54). However, PRF1 p.A91V homozygous 
individuals are reported in studies of healthy populations and 
the risk for disease development in such individuals remains 
unclear (55). In our limited material, the overall frequency of 
this variant was not significantly increased among our ME/CFS 
patients.
Latent CMV infection affects numerous immunological param-
eters (56). In many individuals, an effect of CMV infection is the 
expansion of epigenetically altered adaptive NK cells with limited 
immunoregulatory functions (24, 57). Hypothetically, a genetic 
or epigenetic predisposition in combination with CMV infection 
could generate an immune system with limited immunoregula-
tory capacities. This could explain how common infections might 
cause unremitting inflammation in ME/CFS patients, sparking 
our investigation of adaptive NK cells. We found no indications of 
any differences between ME/CFS patients and controls. To the best 
of our knowledge, this is the first report to study the prevalence of 
adaptive NK cells in the context of ME/CFS.
A central feature of ME/CFS is post-exertional exhaustion 
(4, 58). Notably, β2-adrenergic stimulation can directly inhibit 
cause early-onset familial hemophagocytic lymphohistiocytosis, 
less severe impairments have been associated with a spectrum of 
disorders ranging from hematologic malignancies to neurologic 
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CTL and NK  cell functions (29, 31, 59, 60). Hypothalamic– 
neuroendocrine–adrenal axis dysregulation and other neuroen-
docrine disturbances are features of ME/CFS (18). When probing 
the response inhibition by adrenaline in the Stockholm substudy, 
IFN-γ expression by CD56dim NK  cells was less inhibited by 
adrenaline in cells from ME/CFS patients. This is in line with a 
previous study, showing lower effect of the β2-adrenergic recep-
tor agonist terbutaline on inhibiting monocyte TNF production 
(61). Our potentially confirmatory experiment on the Oslo cohort 
regrettably failed for technical reasons.
In many autoimmune disorders, interactions between multiple 
predisposing factors and environmental triggers cause disease. 
In an attempt to investigate if this could be the case for cytotoxic 
lymphocyte dysfunction and ME/CFS, we deployed both unsu-
pervised and supervised methods considering all investigated 
cytotoxic lymphocyte functional and phenotypic parameters 
together. There was no tendency toward any such reproducible dif-
ference. Furthermore, identifying subgroups among the patients 
based on both clinical observations and laboratory findings was 
not possible. These findings indicate that none of the parameters 
studied here are useful in a clinical setting in differentiating ME/
CFS patients from other individuals. Further strengthening this 
notion, even by increasing the accepted α-error rate to 5%, no 
single parameter was significant for both the Stockholm and the 
Oslo substudies (Figure S3 in Supplementary Material).
It is worth noting that a number of differences were identified in 
the Stockholm substudy, whereas no differences were noted in the 
Oslo substudy. A likely explanation for this is that the Stockholm 
substudy sample collection, PBMC isolation, and freezing pro-
tocols slightly differed between patients and controls, whereas 
the Oslo patient and control samples were handled identically 
in all steps. An arguable difference between the substudies lies 
in the average age that differed 14 years between the Stockholm 
and the Oslo substudies. Our previous work has not shown any 
correlation between age and cytotoxic lymphocyte function (23) 
nor frequency of adaptive NK  cells (24) in healthy individu-
als. Moreover, of the common parameters to these substudies 
exhibiting a p-value lower than 0.1, the highest Pearson product-
moment correlation coefficient to age was 0.3. Hence, the age 
difference between the substudies is unlikely to influence the 
results. In terms of symptoms, patients from Oslo showed higher 
levels of concentration problems than the Stockholm patients 
(Table S1 in Supplementary Material, p = 0.001, significant after 
correction for multiple comparisons), but this was the only 
significant difference between the patient populations. Thus, 
it is unlikely that the discrepancy in the number of differences 
between the substudies can be attributed to differences in the 
patient populations.
Our negative results contrast a number of previously published 
studies indicating diminished NK cell function in ME/CFS (for 
a comprehensive list of relevant publications overall content and 
outcome, see Table S4 in Supplementary Material). A few studies 
have shown that K562 cell killing was diminished in whole-blood 
assays (13, 37). Other studies found similarly diminished NK cell 
cytotoxic activity using PBMC immediately after isolation (15, 46), 
whereas other investigators have not found any impairments of 
NK cell cytotoxic activity using isolated PBMC (16, 62). Timing of 
functional assays vis-à-vis PBMC isolation may explain differences, 
with an effect of soluble factors, such as cytokines, catecholamines, 
and hormones, waning with time from cell isolation from whole 
blood. Such a discrepancy would therefore suggest that NK cells 
from ME/CFS patients in general are intrinsically normal but 
might be responding to an abnormal external milieu, rendering 
them hypofunctional in whole blood or immediately after isola-
tion. Congruently, the addition of adrenaline, as shown above, did 
not attenuate NK cell functionality more in the patients than in 
the controls. If anything, the opposite was observed, which could 
hypothetically be explained by the presence of β2-adrenergic 
receptor autoantibodies (63), or downregulations of β2-adrenergic 
receptors due to an increased tonic adrenergic signaling in the ME/
CFS patients. Regardless, our results indicate that cell intrinsic 
differences in cytotoxic lymphocyte differentiation or function do 
not clearly distinguish ME/CFS patients from controls.
In conclusion, none of the evaluated aspects of cytotoxic 
lymphocyte phenotype or function systematically separated ME/
CFS patients from controls. As such, our investigation does not 
indicate impairments in cytotoxic lymphocyte differentiation 
or function as a major cause of ME/CFS. Thus, these results do 
not support the use of these cytotoxic lymphocyte phenotypic 
or functional examinations for biomarker purposes in clinical 
diagnostic procedures of ME/CFS.
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